Slowing P&C insurance-pricing cycle + soft organic growth (~3–4%) de-rating a full multiple
One-line thesis. Marsh & McLennan is one of the best-run, most recession-resilient businesses in the S&P 500 — a global insurance-brokerage and consulting toll-booth with 26% ROE, low beta, and 15+ years of steady compounding — but it is a mature mid-single-digit organic grower trading right at fair value, so the honest call is Watch: own the quality on a pullback, don't chase it here.
◆ Synthos call — WatchMRSH is a business we want at a price we don't have — it becomes a Buy below ~$180; until then, do nothing.
Downside Risk (lower = safer)
4/10 · Moderate
Low beta (0.61), recession-resilient recurring revenue — but net-debt/EBITDA ~3.1× and 21× trailing leave modest cushion.
Growth Quality
6/10 · High
High-single-digit adj-EPS CAGR, ~24% EBITDA margin, 26% ROE — durable but not fast; ~4% organic.
Exponential Potential
2/10 · Low
Mature megacap broker growing mid-single-digits organically; no acceleration, limited room-to-run — a compounder, not an exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 16%/yrTo justify today’s $179, earnings would have to compound roughly 16% a year for 10 years (9% discount rate). Analysts forecast ~10%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Marsh & McLennan is the middleman that big companies and governments pay to help them buy insurance, manage risk, and run their retirement and health-benefit plans. Think of it as a toll booth: whenever a company needs insurance or advice, Marsh takes a small, steady fee. It owns four famous brands — Marsh (insurance brokerage), Guy Carpenter (reinsurance), Mercer (retirement/health consulting), and Oliver Wyman (management consulting). Because almost every big organization needs this every single year, the money keeps coming even in a recession.
Is the stock cheap or expensive? About fairly priced. You pay roughly 17× next year's expected profit — reasonable for a company this steady, but not a bargain. The stock is actually down about 18% over the past year while the market rose ~21%, so it's out of favor, which is part of what makes it interesting.
Our verdict is Watch — a great company, but priced about right, so we'd rather wait for a dip than pay full freight today.
Here's what our three scores mean in everyday terms:
Downside Risk 4/10 (fairly safe). The business barely wobbles in a downturn and the stock doesn't swing much — but it carries a fair amount of debt and isn't dirt-cheap, so there's modest room to fall.
Growth Quality 6/10 (good, not spectacular). Reliable, profitable, high returns — but it grows slowly and steadily, not fast.
Exponential Potential 2/10 (low). It's already huge and grows in the mid-single-digits. This is a tortoise, not a rocket — own it to compound quietly, never to double quickly.
The one big worry: insurance prices have been rising for years, which lifted Marsh's fees. If that pricing cycle softens and organic growth (~3–4%) slows further, the stock's full valuation could slip.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = MRSH · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$178.54
Market cap$86B
P/E trailing8×
P/E FY26E / FY27E17× / 16×
EV / Sales3.9×
EV / EBITDA16.0×
Gross margin42.4%
Net margin14.3%
Dividend yield2.02%
Beta0.611
52-wk range$157 – $215
RSI(14)63
50 / 200-DMA$165 / $179
12-mo return+-18% (SPY +21%)
Street target$207 ($182–$236)
Analyst grades11 Buy · 21 Hold · 1 Sell
FMP ratingA-
Next earnings2026-08-05
What the experts actually said 0 traceable claims on MRSH · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Marsh & McLennan (NYSE: MRSH; the operating brand is now simply "Marsh") is a ~$86B global professional-services firm — the world's largest insurance broker and risk advisor — employing ~90,000+ people and advising clients in ~130 countries. Fiscal year ends December 31. It runs two segments through four marquee brands:
Risk & Insurance Services (~63% of revenue): Marsh (commercial insurance brokerage) and Guy Carpenter (reinsurance broking). This is the fee-for-placement toll-booth core.
Consulting (~37%): Mercer (health, retirement, wealth and investment consulting) and Oliver Wyman (management/strategy consulting).
The economics are excellent: mostly recurring, capital-light fee revenue with pricing power, a fragmented client base (low single-customer concentration), and secular tailwinds (rising global risk complexity — cyber, climate, litigation — and an aging-workforce/retirement advisory need). It is defensive by construction: clients need risk and benefits advice in every part of the cycle.
Revenue mix (FY2025, from filings/FMP segmentation):
By brand/group: Marsh Insurance Group $31.5B, Mercer $6.19B, Oliver Wyman $3.60B, Guy Carpenter $2.64B (FMP's FY25 brand-level figures gross up some intra-group revenue; the clean two-segment split is Risk & Insurance ~63% / Consulting ~37%, consistent with FY24's $15.4B / $9.1B).
By geography (FY2025): United States $13.34B (49%) · United Kingdom $3.82B (14%) · other geographies $9.90B (37%). Roughly half US, half international — a genuinely global, diversified base.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of MRSH in the Synthos knowledge base.total_claims = 0; there are zero net-bullish (or bearish) voices and zero traceable claim_id values to cite. Per Synthos house standard, we will not manufacture conviction we cannot reconcile to a real claim.
Accordingly, this verdict is entirely fundamentals- and quant-driven: the reported financials (FMP), analyst consensus estimates (labeled as estimates), management's own dated 8-K earnings release (half-weighted, §9), and Synthos's own valuation and scoring model. Where the broader Street sits is shown as context (a Hold consensus, $206.56 average target), not as an anchor. Readers should weight this note accordingly: it carries no independent-expert breadth, only data.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
4 · Low-Moderate
Beta 0.61, recession-resilient recurring revenue and 26% ROE make it structurally sturdy; offsetting that, net-debt/EBITDA ~3.1× is elevated and 21× trailing / 17× forward leaves only a modest valuation cushion.
Growth Quality
6 · Good
~9% adjusted-EPS CAGR, ~24% EBITDA margin, 26% ROE, wide fragmented moat — genuinely high-quality compounding, but only ~4% organic and mid-single-digit revenue growth caps the score.
Exponential Potential
2 · Low
A mature $86B global broker growing revenue ~5% with no acceleration (2nd derivative ~flat-to-down); limited room-to-run. A compounder, not an exponential.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
P&C pricing stays firm, M&A (Marsh has been an active acquirer — $8.5B deployed in FY24) accretes, Thrive efficiency program lands. FY27E adj-EPS beats to ~$11.90 (vs $11.32 cons); multiple re-rates to ~20×.
~$238 (+33%)
Base(our anchor)
Estimates roughly hit — FY27E adj-EPS $11.32; a durable high-single-digit compounder with 24% EBITDA margin earns a ~18× multiple.
Synthos fair value = the base case, ~$205 (+15%), with the full $155–$238 span as the honest range. This anchor sits essentially on top of the Street's $206.56 consensus — we do not see a large mispricing either way, which is precisely why the verdict is Watch rather than Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MRSH is a textbook elite compounder with essentially no exponential character:
Forward growth: revenue CAGR FY25→FY28E ~5.1% ($26.98B → $31.35B); adjusted-EPS CAGR ~9% ($9.60 → $12.33 est), the gap coming from buybacks, margin creep and operating leverage.
Acceleration (the 2nd derivative) is flat-to-negative: revenue growth was +10.3% (FY25, boosted by the McGriff acquisition) decelerating to ~+5% organic-plus going forward. Q1'26 underlying (organic) revenue growth was just +4%. There is no inflection to ride — this is steady-state compounding.
Room to run: at $86B market cap in a mature, well-penetrated brokerage/consulting market, the law of large numbers binds hard. The TAM is large but Marsh already leads it; there is no small-company-in-a-huge-market dynamic here.
Reinvestment runway: primarily inorganic (bolt-on M&A) plus buybacks and a growing dividend — value-accretive but not the kind of high-return organic reinvestment that drives exponential outcomes.
Exponential Potential: Low (2/10). Own MRSH for reliable ~9%-EPS-plus-dividend compounding and downside protection, never for a fast multibagger. A small, accelerating name with these margins would score 8–9; a mature megacap growing mid-single-digits organically honestly scores 2.
Revenue: FY25 $26.98B, +10.3% (FY24 $24.46B, +7.6% on FY23 $22.74B). The FY25 step-up was lifted by the ~$8.5B McGriff acquisition; underlying/organic growth runs ~4–5%.
Quarterly trajectory: Q1'25 $7.06B → Q2 $6.97B → Q3 $6.35B → Q4 $6.60B → Q1'26 $7.60B (+7.6% YoY). Note the strong seasonality — Q1 is the biggest quarter (brokerage renewals).
Margins: gross 42.4% TTM, EBITDA 24.3% TTM, operating ~21.7%, net 14.3% TTM. Consulting is lower-margin than brokerage; blended margins are best-in-class for the sector and slowly expanding.
Earnings: GAAP net income $4.16B FY25 (EPS $8.48; diluted $8.43), up from $4.06B FY24. On the company's adjusted basis (which excludes intangible amortization and noteworthy items) EPS is higher — Q1'26 adjusted EPS was $3.29 vs GAAP $2.36. The consensus estimates in this note are adjusted-EPS.
Balance sheet: total debt $21.4B, net debt $18.76B, net-debt/EBITDA ~2.5–3.1× (elevated after the McGriff-driven debt raise), interest coverage ~6.3×. Investment-grade (FMP letter rating A−) and serviceable, but leverage is the one genuine blemish on an otherwise pristine profile. Goodwill + intangibles are ~$29B (49% of assets) — a function of the acquisitive model; tangible book is negative.
6. Valuation — priced in or room?
MRSH trades at 21× trailing GAAP EPS, 17× FY26E and 16× FY27E adjusted EPS, EV/EBITDA 16×, EV/Sales 3.9×, with a ~2.0% dividend yield. For a business compounding adjusted EPS ~9% with 26% ROE and defensive, recurring revenue, that is a fair — not cheap, not expensive — multiple; it is roughly in line with its own history and its brokerage peers (AON, AJG trade at similar or richer multiples). A simple check: 18× the FY27E adjusted EPS of $11.32 ≈ $204, essentially today's Street target and our base case. The FMP quant model flags the valuation scores as the weak spot (P/E and P/B scores of 2 and 1 out of 5) against elite ROE/ROA/DCF scores (5/5). Street targets (context): consensus $206.56, high $236, low $182, on a Hold rating (1 Strong Buy, 11 Buy, 21 Hold, 1 Sell). Our base case sits right on consensus — there is no obvious margin of safety at $178.54, which is the core reason for the Watch verdict. A pullback toward the low-$160s (a ~15× FY26 multiple) would materially improve the risk/reward.
7. Technicals (from the tech block)
Trend:neutral-to-weak. $178.54 sits just below the 200-DMA ($179.13) but above the 50-DMA ($165.41) — the shorter average has turned up while price hovers around the longer one. No clean uptrend.
Location:−17.0% off the 52-week high ($215.08), +13.5% off the 52-week low ($157.32); max drawdown from peak −26.9% — a meaningful correction has already happened.
Momentum: RSI(14) 63 — firm but not overbought (<70); MACD mildly positive (+1.7). The +3.7% up-day in the latest quote reflects a bounce off the recent lows.
Relative strength (the tell): MRSH is −18.0% over 12 months vs SPY +20.6% and QQQ +30.3% — a sharp, sustained laggard. Over 3 months it is +3.9% (vs SPY +13.7%), still trailing. This is a quality name that has been out of favor, not a momentum leader.
Read: technicals are consistent with the fundamental call — a high-quality business that has de-rated and is basing near its 200-DMA. Not a breakout to chase; a base to accumulate on weakness. A decisive reclaim of the 200-DMA on volume would be the first technical green light.
8. Moat & competitive position
Marsh & McLennan's moat is scale, trust, and switching costs in an oligopolistic industry. In insurance broking it sits in a global "big three" alongside Aon and Arthur J. Gallagher; in reinsurance broking Guy Carpenter is one of two dominant players; Mercer and Oliver Wyman are top-tier consulting brands. Clients rarely switch brokers — relationships, data, and embedded advisory workflows create real stickiness — and the business is capital-light with strong pricing power. The durable risks are (a) disintermediation/technology (management explicitly flags AI and "digital disruption" as competitive factors in its own 8-K), and (b) cyclicality in P&C insurance pricing, which flexes brokerage commissions.
Peer set (market cap): Aon $76B (closest global-broker comp), Arthur J. Gallagher $65B, Willis Towers Watson $27B, Brown & Brown $24B, Chubb $140B (underwriter, not broker), Progressive $136B, Northern Trust $33B, Erie Indemnity $12B. Against AON and AJG, MRSH is the largest and among the highest-quality, trading at a broadly comparable multiple — no obvious relative bargain within the group.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly. FY25 returned ~$1.70B in dividends (raised again; ~2.0% yield, ~44% payout) and ~$2.0B in buybacks, alongside active bolt-on M&A (the ~$8.5B McGriff deal in FY24 was the largest in its history). Capex is minimal (<1% of revenue). The one watch-item is leverage taken on for M&A (net-debt/EBITDA ~3×), which management is deleveraging.
Insider activity: the sampled Form 4s (filed 2026-05-18) are routine director restricted-stock-unit awards/grants (RSUs at $0 cost) — normal board compensation, no discretionary open-market selling signal in the window.
Management's own guidance (the earnings-call track, half-weighted — they talk their book): MRSH's Q1'26 8-K (filed 2026-04-16) is a real earnings release. CEO John Doyle characterized "a solid start to the year" with 8% overall revenue growth, 4% underlying (organic) growth, 8% adjusted operating income growth, and 8% adjusted EPS growth, "in a dynamic and challenging environment." Q1'26 GAAP operating income fell 12% and included a $425M charge related to the Greensill litigation (a real, if likely one-off, legal overhang worth monitoring). Management pointed to its "Thrive" program (brand strategy, client value, growth and efficiency) as the forward operating lever. The release did not contain explicit full-year numeric EPS/revenue guidance (MRSH typically guides qualitatively to "mid-single-digit or better underlying growth, margin expansion, and strong EPS growth"), so we do not attribute a specific forward figure to management. Treat these as management's self-interested framing, half-weighted.
10. Catalysts & what to watch
Next earnings: 2026-07-21 (Q2'26; Street adj-EPS $2.89, revenue ~$7.29B). Key line: underlying/organic revenue growth (is it holding ~4%?) and adjusted operating margin.
P&C insurance pricing cycle: commercial rate trends drive brokerage commissions — the single biggest macro swing factor for the top line.
Underlying (organic) growth trajectory: the market pays a premium for durable mid-single-digit organic growth; a slip toward 2–3% would pressure the multiple.
Greensill litigation: resolution/quantum of the legal matter behind the Q1'26 $425M charge.
M&A + deleveraging: continued accretive bolt-ons while bringing net-debt/EBITDA back toward ~2.5×.
Thesis tripwires (what would change the call): two consecutive quarters of underlying growth below ~3%; adjusted-margin contraction; a valuation re-rate to a genuine discount (mid-$150s) would flip this from Watch toward Buy, while a run to the low-$200s with no estimate revisions would keep it a Watch/trim.
11. Key risks
Valuation / fair-priced (structural): at ~17× forward with our base case on consensus, there is little margin of safety — the primary reason for Watch, not Buy.
Insurance-pricing cyclicality: softening P&C rates directly compress brokerage commissions; organic growth is already only ~4%.
Leverage: net-debt/EBITDA ~3× after McGriff is the one balance-sheet blemish; rising rates or a further debt-funded deal would stretch it.
Litigation/regulatory: the Greensill charge ($425M in Q1'26) and the inherent E&O/fiduciary risk of a broker-advisor.
Disintermediation / AI: management itself flags technological disruption and AI as competitive threats to the advisory model over time.
No expert corroboration: the Synthos KB carries zero independent-analyst claims on this name — the thesis rests solely on data, with no breadth to lean on.
12. Verdict, position sizing & monitoring
Watch. Marsh & McLennan is a genuinely elite business — a low-beta, recession-resilient, 26%-ROE, capital-light compounder with a wide moat and a shareholder-friendly capital plan. But at $178.54 it trades right at fair value: our base-case fair value (~$205) essentially matches the Street's $206.56 consensus and its Hold rating, and there is no margin of safety at today's price. With zero expert coverage in the KB, the call rests purely on fundamentals and quant — and those say "great company, fair price."
Sizing: if bought, a quality-defensive ~2–3% position, scaled in on weakness (toward the low-$160s / ~15× FY26). Today it is a watch, not an add — patience is the edge.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-21). A de-rate into the mid-$150s or a re-acceleration of organic growth would move this toward Buy. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $178.54.
Single biggest risk: a softening insurance-pricing cycle + sub-4% organic growth de-rating a full multiple.
Provenance & disclosures
Traceability: 0 KB claims, breadth 0 — there is no expert coverage of MRSH in the Synthos knowledge base. The verdict is fundamentals- and quant-driven only; no conviction is fabricated (claim-ID reconciliation makes fabrication structurally impossible, and here there are simply no claims to cite).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP) on an adjusted-EPS basis, labeled as estimates.
Management caveat: the Q1'26 8-K commentary in §9 is management's own book, half-weighted by design; no explicit numeric full-year guidance was disclosed in that release.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").